MYX mayne pharma group limited

General Discussion Topics, page-124

  1. 2,540 Posts.
    lightbulb Created with Sketch. 746
    Roger, I would have to agree with this. Another full year of negative growth booked into the annual report is likely in my opinion. Unfortunately for shareholders, MYX would carry such result for another full year on their books before they can attempt to redeem themselves in the FY22 report next August.

    Of course there could be the black swan announcement mid-year, or the half yearly report which may show a huge increase in growth, but based on management past performance, I wouldnt bet my dollar on that occuring. Management past performance of providing negative return on capital invested does not provide confidence that their new investments would differ to provide positive returns on invested capital. The incentives for management to provide shareholder value growth just isnt there either.

    This one is a typical avoid in the books of Ben Graham and David Dodd.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.07
Change
0.050(1.00%)
Mkt cap ! $411.9M
Open High Low Value Volume
$5.00 $5.14 $4.94 $712.4K 141.2K

Buyers (Bids)

No. Vol. Price($)
1 1059 $5.07
 

Sellers (Offers)

Price($) Vol. No.
$5.13 1000 1
View Market Depth
Last trade - 16.10pm 26/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.